Select to view the solutions available in your location.
Track orders, get results, manage personal information, and more.
Order tests, track orders, get results, and more.
Learn more about our innovative products and services that help detect cancer earlier and power smarter treatment decisions.
Exact Sciences plans to introduce the Cologuard Plus™ test in 2025, building on a decade of patient impact.
Find out how our scientific rigor, quality standards, and development of future tests make us a leader in cancer testing and treatment guidance.
How one revolutionary test could change the health of millions.
Learn all about Exact Sciences, including our purpose, the people who drive it, our history, and the impact we’ve made.
Several Exact Sciences initiatives address disparities in cancer outcomes among U.S. Latinos.
Explore stories, news, and events that highlight our innovation, technology, and people fighting cancer on all fronts.
Insights from the Alpha-CORRECT clinical validation study
At Exact Sciences, we are developing leading-edge cancer diagnostics to improve patient outcomes. Our latest innovation comes from the Alpha-CORRECT clinical validation study, a landmark study that underscores our commitment to innovation in the detection of molecular residual disease (MRD) in colorectal cancer. This week, we shared our findings at the annual ASCO Gastrointestinal Cancers Symposium conference and concurrently published them in the Journal of Surgical Oncology.
The Alpha-CORRECT study is an important milestone in our efforts to guide personalized cancer testing. This study focused on stage III colorectal cancer patients and utilized the OncodetectTM molecular residual disease (MRD) test to detect circulating tumor DNA (ctDNA) in a patient’s blood. The findings from this study further validate the transformative capabilities of MRD testing in monitoring cancer patients after treatment.
The Alpha-CORRECT study findings highlight the clinical validity of the Oncodetect test in providing a precise assessment of a patient’s risk of cancer recurrence. For instance, patients with ctDNA detected post-surgery had a recurrence rate nearly 10 times higher than those without detectable ctDNA. Similarly, patients with ctDNA detected after chemotherapy had a recurrence rate nearly 17 times higher. Conversely, only about 2% of patients with persistently negative ctDNA tests during Alpha-CORRECT — one of the longest MRD surveillance studies to date — experienced cancer recurrence.
The Oncodetect test aims to give health care professionals deeper insights into a patient's MRD status over time, facilitating more informed decision-making and personalized treatment plans.
The Alpha-CORRECT study is the first published study showing the potential for Oncodetect to empower doctors to deliver more impactful care for their patients.
As we continue to innovate, this study reinforces our dedication to transforming cancer detection and improving lives. Stay tuned as we build on this success, share additional clinical evidence and work toward a future where cancer is caught earlier and managed with precision.
1. Diergaarde B, et al. Circulating Tumor DNA as a Marker of Recurrence Risk in Stage III Colorectal Cancer: The α-Correct Study. Journal of Surgical Oncology. January 25, 2025.
Emily Pinto
Read more »
Exact Sciences